Annual CFF
-$347.96 M
-$1.82 B-123.67%
31 December 2022
Summary:
Horizon Therapeutics Public Limited annual cash flow from financing activities is currently -$347.96 million, with the most recent change of -$1.82 billion (-123.67%) on 31 December 2022. During the last 3 years, it has fallen by -$1.25 billion (-138.47%). HZNP annual CFF is now -123.67% below its all-time high of $1.47 billion, reached on 31 December 2021.HZNP Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$9.03 M
+$97.16 M+110.25%
30 June 2023
Summary:
Horizon Therapeutics Public Limited quarterly cash flow from financing activities is currently $9.03 million, with the most recent change of +$97.16 million (+110.25%) on 30 June 2023. HZNP quarterly CFF is now -99.39% below its all-time high of $1.47 billion, reached on 31 March 2021.HZNP Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
-$334.43 M
-$8.38 M-2.57%
30 June 2023
Summary:
Horizon Therapeutics Public Limited TTM cash flow from financing activities is currently -$334.43 million, with the most recent change of -$8.38 million (-2.57%) on 30 June 2023. HZNP TTM CFF is now -113.86% below its all-time high of $2.41 billion, reached on 31 March 2021.HZNP TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
HZNP Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -138.5% | +209.4% | -122.8% |
| 5 y5 years | -1996.6% | +114.2% | -14.0% |
HZNP Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -123.7% | at low | -48.1% | +105.6% | -122.8% | +3.9% |
| 5 y | 5 years | -123.7% | at low | -99.4% | +105.6% | -113.9% | +4.6% |
| alltime | all time | -123.7% | at low | -99.4% | +103.5% | -113.9% | +4.6% |
Horizon Therapeutics Public Limited Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | $9.03 M(-110.3%) | -$334.43 M(+2.6%) |
| Mar 2023 | - | -$88.13 M(-45.3%) | -$326.05 M(-6.3%) |
| Dec 2022 | -$347.96 M(-123.7%) | -$160.97 M(+70.6%) | -$347.96 M(+96.3%) |
| Sept 2022 | - | -$94.37 M(-641.9%) | -$177.28 M(+94.5%) |
| June 2022 | - | $17.42 M(-115.8%) | -$91.16 M(-16.4%) |
| Mar 2022 | - | -$110.04 M(-1233.0%) | -$109.11 M(-107.4%) |
| Dec 2021 | $1.47 B(+62.5%) | $9.71 M(-217.6%) | $1.47 B(+0.4%) |
| Sept 2021 | - | -$8.26 M(+1463.4%) | $1.46 B(-38.8%) |
| June 2021 | - | -$528.00 K(-100.0%) | $2.39 B(-0.9%) |
| Mar 2021 | - | $1.47 B(>+9900.0%) | $2.41 B(+166.8%) |
| Dec 2020 | $904.58 M(-411.4%) | $4.10 M(-99.6%) | $904.58 M(-0.9%) |
| Sept 2020 | - | $919.63 M(+4392.3%) | $912.87 M(-1393.5%) |
| June 2020 | - | $20.47 M(-151.7%) | -$70.57 M(-79.9%) |
| Mar 2020 | - | -$39.61 M(-419.8%) | -$350.68 M(+20.7%) |
| Dec 2019 | -$290.45 M(+1650.1%) | $12.39 M(-119.4%) | -$290.45 M(-1.0%) |
| Sept 2019 | - | -$63.81 M(-75.4%) | -$293.29 M(+29.1%) |
| June 2019 | - | -$259.64 M(-1359.1%) | -$227.11 M(-2708.1%) |
| Mar 2019 | - | $20.62 M(+116.0%) | $8.71 M(-152.5%) |
| Dec 2018 | -$16.60 M(-130.6%) | $9.54 M(+304.4%) | -$16.60 M(-63.6%) |
| Sept 2018 | - | $2.36 M(-109.9%) | -$45.53 M(-1.2%) |
| June 2018 | - | -$23.82 M(+408.6%) | -$46.09 M(+114.2%) |
| Mar 2018 | - | -$4.68 M(-75.9%) | -$21.52 M(-139.6%) |
| Dec 2017 | $54.28 M(-91.7%) | -$19.39 M(-1174.3%) | $54.28 M(-92.6%) |
| Sept 2017 | - | $1.80 M(+140.3%) | $732.43 M(+0.2%) |
| June 2017 | - | $751.00 K(-98.9%) | $730.78 M(-0.2%) |
| Mar 2017 | - | $71.11 M(-89.2%) | $732.45 M(+11.5%) |
| Dec 2016 | $657.07 M | $658.76 M(>+9900.0%) | $657.07 M(>+9900.0%) |
| Sept 2016 | - | $151.00 K(-93.8%) | $204.00 K(-92.2%) |
| June 2016 | - | $2.42 M(-156.8%) | $2.61 M(-99.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2016 | - | -$4.27 M(-325.2%) | $1.04 B(-27.9%) |
| Dec 2015 | $1.44 B(+326.4%) | $1.89 M(-25.8%) | $1.44 B(-0.3%) |
| Sept 2015 | - | $2.55 M(-99.8%) | $1.45 B(-17.0%) |
| June 2015 | - | $1.04 B(+160.9%) | $1.74 B(+144.6%) |
| Mar 2015 | - | $398.50 M(+6206.3%) | $712.63 M(+110.7%) |
| Dec 2014 | $338.29 M(+407.1%) | $6.32 M(-97.9%) | $338.29 M(-15.5%) |
| Sept 2014 | - | $298.55 M(+3123.4%) | $400.43 M(+297.0%) |
| June 2014 | - | $9.26 M(-61.7%) | $100.87 M(+11.0%) |
| Mar 2014 | - | $24.16 M(-64.7%) | $90.87 M(+36.2%) |
| Dec 2013 | $66.72 M(-59.4%) | $68.46 M(-6878.3%) | $66.72 M(-4210.7%) |
| Sept 2013 | - | -$1.01 M(+37.4%) | -$1.62 M(-102.0%) |
| June 2013 | - | -$735.00 K(<-9900.0%) | $80.19 M(-1.0%) |
| Mar 2013 | - | $0.00(-100.0%) | $80.96 M(-50.7%) |
| Dec 2012 | $164.31 M(+197.9%) | $122.00 K(-99.8%) | $164.31 M(+0.1%) |
| Sept 2012 | - | $80.80 M(>+9900.0%) | $164.22 M(+28.6%) |
| June 2012 | - | $41.00 K(-100.0%) | $127.68 M(-5.3%) |
| Mar 2012 | - | $83.34 M(>+9900.0%) | $134.82 M(+144.4%) |
| Dec 2011 | $55.15 M(+85.3%) | $39.00 K(-99.9%) | $55.15 M(+1.8%) |
| Sept 2011 | - | $44.26 M(+516.6%) | $54.17 M(+142.3%) |
| June 2011 | - | $7.18 M(+95.1%) | $22.36 M(-33.8%) |
| Mar 2011 | - | $3.68 M(-489.3%) | $33.78 M(+13.5%) |
| Dec 2010 | $29.76 M(+151.3%) | -$945.00 K(-107.6%) | $29.76 M(-18.7%) |
| Sept 2010 | - | $12.45 M(-33.1%) | $36.62 M(+14.5%) |
| June 2010 | - | $18.60 M(-5491.9%) | $31.97 M(+161.1%) |
| Mar 2010 | - | -$345.00 K(-105.8%) | $12.24 M(+3.4%) |
| Dec 2009 | $11.84 M(-34.2%) | $5.91 M(-24.2%) | $11.84 M(+99.7%) |
| Sept 2009 | - | $7.80 M(-792.8%) | $5.93 M(-416.7%) |
| June 2009 | - | -$1.13 M(+50.9%) | -$1.87 M(+150.9%) |
| Mar 2009 | - | -$746.00 K | -$746.00 K |
| Dec 2008 | $18.00 M | - | - |
FAQ
- What is Horizon Therapeutics Public Limited annual cash flow from financing activities?
- What is the all time high annual CFF for Horizon Therapeutics Public Limited?
- What is Horizon Therapeutics Public Limited quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Horizon Therapeutics Public Limited?
- What is Horizon Therapeutics Public Limited TTM cash flow from financing activities?
- What is the all time high TTM CFF for Horizon Therapeutics Public Limited?
What is Horizon Therapeutics Public Limited annual cash flow from financing activities?
The current annual CFF of HZNP is -$347.96 M
What is the all time high annual CFF for Horizon Therapeutics Public Limited?
Horizon Therapeutics Public Limited all-time high annual cash flow from financing activities is $1.47 B
What is Horizon Therapeutics Public Limited quarterly cash flow from financing activities?
The current quarterly CFF of HZNP is $9.03 M
What is the all time high quarterly CFF for Horizon Therapeutics Public Limited?
Horizon Therapeutics Public Limited all-time high quarterly cash flow from financing activities is $1.47 B
What is Horizon Therapeutics Public Limited TTM cash flow from financing activities?
The current TTM CFF of HZNP is -$334.43 M
What is the all time high TTM CFF for Horizon Therapeutics Public Limited?
Horizon Therapeutics Public Limited all-time high TTM cash flow from financing activities is $2.41 B